D. Sleijfer

Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis.

N. Mulder, E. de Vries, J. Buter, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients.

L. de Leij, J. Buter, T. The, 1995, British Journal of Cancer.

Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.

I. Karlberg, E. D. Vries, N. Mulder, 1990, British Journal of Cancer.

Acute and cumulative effects of carboplatin on renal function.

E. Smit, P. Postmus, D. Sleijfer, 1989, British Journal of Cancer.

Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer.

J. Habbema, E. Steyerberg, S. Fosså, 1996, British Journal of Cancer.

Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer.

H. Hoekstra, J. Gietema, W. T. van der Graaf, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.

L. Collette, R. Sylvester, A. V. van Oosterom, 1998, British Journal of Cancer.

Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.

H. Groen, N. Mulder, E. de Vries, 1997, British Journal of Cancer.

Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer.

N. Mulder, E. de Vries, P. Willemse, 1997, British Journal of Cancer.